Cellectar Biosciences CLRB

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
+$0.01 (+2.78%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

Relative Strength Index (RSI)

- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

- The RSI is calculated using the following formula:

RSI = 100 - (100 / (1 + RS))

Where RS is the ratio of the average gains to the average losses over a specified period.

- The default time period used is 14 days.

- RSI values range between 0 and 100.

RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

About

Cellectar Biosciences (CLRB) Business Model and Operations Summary
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.

Key Insights

Cellectar Biosciences (CLRB) Core Market Data and Business Metrics
  • Latest Closing Price

    $0.255
  • Market Cap

    $11.65 Million
  • Total Outstanding Shares

    46.08 Million Shares
  • Total Employees

    11
  • IPO Date

    April 19, 2005
  • SIC Description

    Pharmaceutical Preparations
  • Primary Exchange

    NASDAQ
  • Headquarters

    100 Campus Drive, Florham Park, NJ, 07932

Earnings Reports

Expected vs. Actual Quarterly Earnings-Per-Share & Revenue

Short Volume

Daily short volume activity identifies short-term trading pressure and potential price volatility

Revenue Breakdown

Distribution of revenue across unique business segments & geographies

Historical Stock Splits

Execution DateSplit Amount

Historical Dividends

Recent Headlines From The Web

Latest news, press releases, and media coverage about CLRB from trusted financial sources